Contact Us
TEL: +86-0571-88334626
Home > News > Content
Jun 29, 2018

Daptomycin is a cyclic lipopeptide antibiotic originally developed by Lilly (Lilly) and Cubist pharmaceuticals. Deal with resistance to new antibiotics the pressing needs of the patient, at the end of 2003, the United States food and drug administration (FDA) following a quick trial program approval for injection of tora toxin (Daptomycin) (trade name cubicin) used to treat some gram positive strains of the sensitive concurrency skin and skin structure infections, such as abscess, infection of incision and skin ulcers. Of different mechanism of the drug, and other antibiotics, it by disrupting the cell membrane transport of amino acids, which hinder the biosynthesis of bacterial cell wall peptidoglycan, change the nature of the cytoplasmic membrane; In addition, it can also sterilize bacteria by destroying their cell membranes and allowing their contents to leak out. Therefore, it may be difficult for bacteria to develop resistance to datoramycin.